We are live on ! Find out more
IOVA icon

Iovance Biotherapeutics
IOVA

251 hedge funds and large institutions have $4.98B invested in Iovance Biotherapeutics in 2021 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 98 increasing their positions, 77 reducing their positions, and 58 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more call options, than puts

Call options by funds: $37.9M | Put options by funds: $18.9M

27% more repeat investments, than reductions

Existing positions increased: 98 | Existing positions reduced: 77

5.5% more ownership

Funds ownership: 101.41% → 106.9% (+5.5%)

7% less funds holding

Funds holding: 269 → 251 (-18)

28% less capital invested

Capital invested by funds: $6.9B → $4.98B (-$1.92B)

29% less first-time investments, than exits

New positions opened: 41 | Existing positions closed: 58

36% less funds holding in top 10

Funds holding in top 10: 11 → 7 (-4)

Holders
251
Holders Change
-18
Holders Change %
-6.69%
% of All Funds
4.41%
Holding in Top 10
7
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-36.36%
% of All Funds
0.12%
New
41
Increased
98
Reduced
77
Closed
58
Calls
$37.9M
Puts
$18.9M
Net Calls
+$18.9M
Net Calls Change
-$23.1M

Top Buyers

1
AIM
ARK Investment Management
Florida
+$184M
2
Deutsche Bank
Deutsche Bank
Germany
+$181M
3
CS
Credit Suisse
Switzerland
+$98.2M
4
Wellington Management Group
Wellington Management Group
Massachusetts
+$67.8M
5
Goldman Sachs
Goldman Sachs
New York
+$48.6M

Top Sellers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$93.1M
2
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$86.5M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$53.9M
4
FCM
Farallon Capital Management
California
-$51.8M
5
CCM
Consonance Capital Management
New York
-$38.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
FTUS
276
Flow Traders U.S.
New York
– -$306K -6,600 Closed
MFS
277
Mirabella Financial Services
United Kingdom
– -$297K -6,400 Closed
HSBC Holdings
278
HSBC Holdings
United Kingdom
– -$271K -5,777 Closed
Qube Research & Technologies (QRT)
279
Qube Research & Technologies (QRT)
United Kingdom
– -$262K -5,652 Closed
AR
280
Advisory Research
Illinois
– -$257K -5,543 Closed
EDRH
281
Edmond de Rothschild Holding
Switzerland
– -$257K -5,543 Closed
LPL Financial
282
LPL Financial
California
– -$254K -5,465 Closed
GCP
283
GSA Capital Partners
United Kingdom
– -$247K -5,321 Closed
IRF
284
IBM Retirement Fund
New York
– -$238K -5,124 Closed
XS
285
XR Securities
Illinois
– -$230K -4,963 Closed
DCM
286
Dupont Capital Management
Delaware
– -$226K -4,869 Closed
Comerica Bank
287
Comerica Bank
Texas
– -$218K -4,590 Closed
DBIA
288
Dumont & Blake Investment Advisors
New Jersey
– -$211K -4,550 Closed
JGGDR
289
JGP Global Gestao de Recursos
Brazil
– -$211K -4,544 Closed
CA
290
Calton & Associates
Florida
– -$209K -4,500 Closed
PCM
291
Prelude Capital Management
New York
– -$208K -4,481 Closed
WA
292
Wealth Alliance
New York
– -$204K -4,400 Closed
Parallax Volatility Advisers
293
Parallax Volatility Advisers
California
– -$45K -969 Closed
RE
294
RBC Europe
United Kingdom
– -$13.7K -295 Closed
Loomis, Sayles & Company
295
Loomis, Sayles & Company
Massachusetts
– -$13K -277 Closed
IA
296
IFP Advisors
Florida
– -$2.53K -61 -94%
RPWA
297
Regent Peak Wealth Advisors
Georgia
– -$3K -58 Closed
ICP
298
Interchange Capital Partners
Pennsylvania
– -$2K -51 Closed
QT
299
Quantbot Technologies
New York
– -$2K -49 Closed
PWPS
300
Pinnacle Wealth Planning Services
Ohio
– -$2K -37 Closed
9 10 11
12
13

IOVA Hedge Fund Activity: Q1 2021 in Review

251 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q1 2021, worth a combined $4.98B — down 28% from $6.9B a quarter earlier.

Sellers outnumbered buyers: 58 funds closed out of IOVA and 41 opened new positions — a net loss of 17 holders — while 77 trimmed existing stakes and 98 added.

The largest buyer was ARK Investment Management, adding an estimated $184M. The largest seller was T. Rowe Price Associates, cutting an estimated $93.1M.

  • 251 institutional investors held Iovance Biotherapeutics (IOVA) as of Q1 2021, down from 269 in Q4 2020.
  • Funds reported $4.98B of Iovance Biotherapeutics stock for Q1 2021, down 28% quarter-over-quarter.
  • 41 funds opened new Iovance Biotherapeutics positions in Q1 2021 and 58 closed out, a net change of -17 holders.
  • The largest Iovance Biotherapeutics buyer in Q1 2021 was ARK Investment Management, an estimated $184M added.
  • The largest Iovance Biotherapeutics seller in Q1 2021 was T. Rowe Price Associates, an estimated $93.1M sold.

Based on aggregated 13F filings for Q1 2021.